EUVIMEDEUVIMED entdecken
Systematische Übersicht

The impact of dupilumab on skin barrier function: A systematic review

Trinidad Montero-Vilchez iD, Raquel Sanabria-de-la-Torre, Manuel Sanchez-Diaz iD, Clara Ureña-Paniego, Alejandro Molina-Leyva iD, Salvador Arias-Santiago

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19081 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Trinidad Montero-Vilchez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Virgen de las Nieves University Hospital, Granada, Spain. Hauptthemen laut MEDLINE: Water Loss, Insensible, Dermatitis, Atopic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin barrier dysfunction plays an important role in atopic dermatitis (AD) aetiopathogenesis. Dupilumab, a drug that inhibits IL‐4 and IL‐13, is an effective treatment for AD but there is scarce evidence about its impact on epidermal barrier. The objective of this systematic review is to evaluate the influence of dupilumab on skin barrier in patients with AD using non‐invasive tools. A systematic review was designed following PRISMA guidelines. The literature search identified 73 references and, finally, only 6 were selected, including a total of 233 participants. All the studies were prospective observational studies. Dupilumab improved clinical scores in all the research. Skin barrier function parameters were mainly measured on the volar forearm. Transepidermal water loss (TEWL) was the parameter most frequently measured, evaluated in all the studies. Dupilumab decreased TEWL on eczematous lesions and non‐involved skin. About 33.6% (2/6) studies reported that dupilumab also increased stratum corneum hydration (SCH) on eczematous lesions while one study did not report any changes in this parameter. This drug also decreased temperature and improved ceramide composition. In conclusion, dupilumab improved skin barrier function in AD patients, mainly reflected in a decreased in TEWL values.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Water Loss, InsensibleDermatitis, AtopicHumansSkinEpidermisObservational Studies as TopicAntibodies, Monoclonal, Humanized

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, Virgen de las Nieves University Hospital, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • Dermatology Department, Faculty of Medicine, University of Granada, Granada, 18001, Spain.

ORCID-Profile: Trinidad Montero-Vilchez, Manuel Sanchez-Diaz, Alejandro Molina-Leyva

Zitieren

APA

Montero-Vilchez, T., Sanabria-de-la-Torre, R., Sanchez-Diaz, M., Ureña-Paniego, C., Molina-Leyva, A., & Arias-Santiago, S. (2023). The impact of dupilumab on skin barrier function: A systematic review. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19081

Vancouver

Montero-Vilchez T, Sanabria-de-la-Torre R, Sanchez-Diaz M, Ureña-Paniego C, Molina-Leyva A, Arias-Santiago S. The impact of dupilumab on skin barrier function: A systematic review. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19081

BibTeX
@article{MonteroVilchez2023,
  author = {Montero-Vilchez, Trinidad and Sanabria-de-la-Torre, Raquel and Sanchez-Diaz, Manuel and Ureña-Paniego, Clara and Molina-Leyva, Alejandro and Arias-Santiago, Salvador},
  title = {The impact of dupilumab on skin barrier function: A systematic review},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19081}
}
Kostenlos starten →